There are many articles today that you can read about Oncotarget, but many of them could probably be just write-ups that have nothing really good to say. Most of these articles are written by fledgling writers who are paid to do so.
In this article, we will address that and solve the issue by only offering you what we think you really need. We want to offer you the essentials. We want only to offer you the things that will be useful to you. How? Just read below for more of the info. Listen to Oncotarget podcast on Player.FM.
The Latest Report From ResearchGate
There are so many things happening in the research efforts of Oncotarget, but one of the latest and most updated things today would be the one about FOX06.
In the ResearchGate website, it is reported that one one of the many factors that contribute to FOXO genes and to carcinogenesis in the breast would have a lot to do with FOX06, which are the basic transcriptional factors in mammals.
There’s a lot of statistical analysis brought about by the study, and one of them would involve the role of FOXO family in understanding the roots of breast cancer. It is also in the research from ResearchGate about Oncotarget that you can read about the expression of breast cell lines and breast tumors in the human body. Listen to Oncotarget podcast on Stitcher.
Oncotarget’s Research on Thyroid Cancer
Other than the discussion on the role of FOXO gene expression, you may probably already heard about the involvement of Oncotarget in finding new therapies for thyroid cancer.
This new set of therapies from Oncotarget was reported from Eureka Alert, and in the report, it is shown through a Harvard Medical School report that an FDA-approved drug called palbociclib has been used as a breast cancer therapy for those who want to have better options. Cancer patients who need a respite from the drugs they’re taking that have been proven ineffective can see a lot of good from this new introduction presented by Oncotarget.
That said, there are so many things that can still be expected in thyroid cancer therapy, and it’s good to know that we have Oncotarget who will feature each and every one of them.